Literature DB >> 2572245

Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat.

L Vécsei1, R Ekman, C Alling, E Widerlöv.   

Abstract

Cysteamine (1.95 or 3.90 mM/kg) administered subcutaneously (sc) markedly decreased the open-field activity of the rats, while the structurally related amino acid cysteine had only minor influence. Cysteamine (1.95 or 3.90 mM/kg) reduced the noradrenaline and increased the dopamine and dihydroxyphenyl acetic acid (DOPAC) levels in the hypothalamus. In striatum the drug decreased both the noradrenaline (1.95 or 3.90 mM/kg) and dopamine (3.90 mM/kg) levels without influencing the DOPAC content. Neither the hypothalamic nor the striatal catecholamines are influenced by administration of equimolar doses of cysteine. Cysteamine (1.95 or 3.90 mM/kg) decreased the somatostatin levels both in the hypothalamus and in the striatum without influencing neuropeptide Y (NPY) and corticotropin releasing hormone (CRH) concentrations. Cysteine administered in equimolar doses did not influence the peptide levels in these brain structures. These data suggest that the cysteamine-induced behavioural changes are related to the decrease of brain noradrenaline and somatostatin concentrations. The structurally related amino acid cysteine does not influence the behaviour or the central monoaminergic and peptidergic concentrations in the hypothalamus and striatum of rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572245     DOI: 10.1007/BF01249230

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

1.  Comparative studies with cyclic and linear somatostatin on active avoidance behaviour and open-field activity in rats.

Authors:  L Vécsei; I Bollók; G Telegdy
Journal:  Acta Physiol Hung       Date:  1983

2.  Cysteamine: a potent and specific depletor of pituitary prolactin.

Authors:  W J Millard; S M Sagar; D M Landis; J B Martin
Journal:  Science       Date:  1982-07-30       Impact factor: 47.728

3.  Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment.

Authors:  E Widerlöv; R Ekman; L Jensen; L Borglund; K Nyman
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  Pantetheinase activity and cysteamine content in cystinotic and normal fibroblasts and leukocytes.

Authors:  S Orloff; J D Butler; D Towne; A B Mukherjee; J D Schulman
Journal:  Pediatr Res       Date:  1981-07       Impact factor: 3.756

5.  Biochemical changes in tissue catecholamines and serotonin in duodenal ulceration caused by cysteamine or propionitrile in the rat.

Authors:  S Szabo; H C Horner; H Maull; J Schnoor; C C Chiueh; M Palkovits
Journal:  J Pharmacol Exp Ther       Date:  1987-03       Impact factor: 4.030

6.  Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons.

Authors:  B M Chronwall; T N Chase; T L O'Donohue
Journal:  Neurosci Lett       Date:  1984-12-21       Impact factor: 3.046

7.  Comparative studies with somatostatin and cysteamine in different behavioral tests on rats.

Authors:  L Vécsei; C Király; I Bollók; A Nagy; J Varga; B Penke; G Telegdy
Journal:  Pharmacol Biochem Behav       Date:  1984-12       Impact factor: 3.533

8.  Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography--electrochemical detection system.

Authors:  O Magnusson; L B Nilsson; D Westerlund
Journal:  J Chromatogr       Date:  1980-12-12

9.  The relationship between amphetamine antagonism and depletion of brain catecholamines by alpha-methyl-p-tyrosine in rats.

Authors:  E Widerlöv; T Lewander
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

10.  Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively.

Authors:  E Widerlöv; L H Lindström; C Wahlestedt; R Ekman
Journal:  J Psychiatr Res       Date:  1988       Impact factor: 4.791

View more
  4 in total

1.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

2.  Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies.

Authors:  François Gastambide; Cécile Viollet; Gabriel Lepousez; Jacques Epelbaum; Jean-Louis Guillou
Journal:  Psychopharmacology (Berl)       Date:  2008-06-03       Impact factor: 4.530

3.  Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Sulail Fatima; Tabassom Beiranvand; Shiva Mozaffari
Journal:  J Neural Transm (Vienna)       Date:  2017-08-09       Impact factor: 3.575

4.  Somatostatin 1.1 contributes to the innate exploration of zebrafish larva.

Authors:  Feng B Quan; Laura Desban; Olivier Mirat; Maxime Kermarquer; Julian Roussel; Fanny Koëth; Hugo Marnas; Lydia Djenoune; François-Xavier Lejeune; Hervé Tostivint; Claire Wyart
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.